Clinical Trials Logo

Clinical Trial Summary

This trial is a phase II, multi-center, single-masked (assessors) dose-ranging study designed to evaluate the comparative safety and preliminary efficacy of two dosage regimens of the IBE-814 IVT Dexamethasone Implant in patients with DMO and RVO.


Clinical Trial Description

The study will enroll up to 50 patients (up to 50 eyes) with DMO or RVO across two treatment groups (Low Dose and High Dose). Patients will be identified and recruited through the clinic population of ophthalmology centers in Australia and New Zealand, specializing in the diagnosis and treatment of retinal diseases. All patients will be followed for a planned evaluation period of 18 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04576689
Study type Interventional
Source Ripple Therapeutics Corporation
Contact
Status Active, not recruiting
Phase Phase 2
Start date October 30, 2020
Completion date August 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT02554747 - Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa N/A
Withdrawn NCT02309476 - Sub-threshold Photocoagulation of Diabetic Macular Oedema N/A
Terminated NCT02207712 - Noctura400 Treatment for Diabetic Retinopathy (CANDLE) N/A
Completed NCT02457884 - Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema N/A
Completed NCT00148330 - Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study Phase 2/Phase 3
Completed NCT03495765 - To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus Phase 3
Completed NCT00167518 - Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO) Phase 2/Phase 3
Completed NCT01787669 - Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema Phase 2
Completed NCT01175070 - Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Phase 4
Terminated NCT00427986 - Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema N/A
Completed NCT00333671 - Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema) N/A
Completed NCT02731911 - Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
Completed NCT00148265 - A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema Phase 2/Phase 3
Completed NCT02181400 - Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema N/A